A novel honokiol liposome: formulation, pharmacokinetics, and antitumor studies

References

• Ochwang’i DO, Kimwele CN, Oduma JA, et al. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol. 2014;151:1040–1055.
   PubMed Web of Science ®Google Scholar
• Hede S, Huilgol N. “Nano”: the new nemesis of cancer. J Cancer Res Ther. 2006;2:186–195.
   PubMedGoogle Scholar
• Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Ijn. 2017;12:2689–2702.
   Google Scholar
• Alexander A, Ajazuddin Patel RJ, et al. Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release 2016;10;241:110–124.
   Google Scholar
• Wang X, Wang YQ, Chen Z, et al. Advances of cancer therapy by nanotechnology. Cancer Res Treat. 2009;41:1–11.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang Q, Yang G, et al. Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography. J Chromatogr A. 2007;1142:115–122.
   PubMed Web of Science ®Google Scholar
• Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res. 1988;50:757–765.
   PubMed Web of Science ®Google Scholar
• Syu WJ, Shen CC, Lu JJ, et al. Antimicrobial and cytotoxic activities of neolignans from Magnolia officinalis. C&B. 2004;1:530–537.
   Google Scholar
• Liou KT, Shen YC, Chen CF, et al. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol. 2003;475:19–27.
   PubMed Web of Science ®Google Scholar
• Dikalov S, Losik T, Arbiser JL. Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol. 2008;76:589–596.
   PubMed Web of Science ®Google Scholar
• Pyo MK, Lee YY, Yun-Choi HS. Anti-platelet effect of the constituents isolated from the barks and fruits of Magnolia obovata. Arch Pharm Res. 2002;25:325–328.
   PubMed Web of Science ®Google Scholar
• Kuribara H, Kishi E, Hattori N, et al. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. J Pharm Pharmacol. 2000;52:1425–1429.
   PubMed Web of Science ®Google Scholar
• Qiu N, Cai LL, Xie DC, et al. Synthesis, structural and in vitro studies of well-dispersed monomethoxy-poly(ethylene glycol)-honokiol conjugate micelles. Biomed Mater. 2010;5:065006.
   PubMed Web of Science ®Google Scholar
• Bai XH, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278:35501–35507.
   PubMed Web of Science ®Google Scholar
• Li ZY, Liu Y, Zhao X, et al. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gyn R B. 2008;140:95–102.
   PubMed Web of Science ®Google Scholar
• Wen J, Fu AF, Chen LJ, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009; Jun 1124:2709–2718.
   Google Scholar
• Yang JH, Pei HY, Luo H, et al. Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget 2017;8:915–932.
   PubMedGoogle Scholar
• Crane C, Panner A, Pieper RO, et al. Honokiol-mediated Inhibition of PI3K/mTOR pathway a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother. 2009;32:585–592.
   PubMed Web of Science ®Google Scholar
• Rajendran P, Li F, Shanmugam MK, et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J Cell Physiol. 2012;227:2184–2195.
   PubMed Web of Science ®Google Scholar
• Tse AKW, Wan CK, Shen XL, et al. Honokiol inhibits TNF-alpha-stimulated NF-kappa B activation and NF-kappa B-regulated gene expression through suppression of IKK activation. Biochem Pharmacol. 2005;70:1443–1457.
   PubMed Web of Science ®Google Scholar
• Wang X, Deng L, Cai L, et al. Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-beta-cyclodextrin-in-liposome. J Pharm Sci. 2011;100:3357–3364.
   PubMed Web of Science ®Google Scholar
• Wang XH, Cai LL, Zhang XY, et al. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharmaceut. 2011;410:169–174.
   PubMed Web of Science ®Google Scholar
• Hu J, Chen LJ, Liu L, et al. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med. 2008;40:617–628.
   PubMed Web of Science ®Google Scholar
• Jiang QQ, Fan LY, Yang GL, et al. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer. 2008;8:242.
   PubMed Web of Science ®Google Scholar
• Yang JH, Wu WS, Wen JL, et al. Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells. Biomaterials 2017;141:188–198.
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(Ethylene Glycol) show prolonged circulation half-lives invivo. Biochimica Et Biophysica Acta. 1991;1066:29–36.
   PubMed Web of Science ®Google Scholar
• Date AA, Nagarsenker MS. Design and evaluation of microemulsions for improved parenteral delivery of propofol. AAPS PharmSciTech. 2008;9:138–145.
   PubMed Web of Science ®Google Scholar
• Seo SW, Han HK, Chun MK, et al. Preparation and pharmacokinetic evaluation of curcumin solid dispersion using Solutol (R) HS15 as a carrier. Int J Pharmaceut. 2012;424:18–25.
   PubMed Web of Science ®Google Scholar
• Scheller KJ, Williams SJ, Lawrence AJ, et al. An improved method to prepare an injectable microemulsion of the galanin-receptor 3 selective antagonist, SNAP 37889, using Kolliphor((R)) HS 15. MethodsX 2014;1:212–216.
   PubMedGoogle Scholar
• Illum L, Jordan F, Lewis AL, CriticalSorb™. A novel efficient nasal delivery system for human growth hormone based on Solutol HS15. J Control Release. 2012;162:194–200.
   PubMed Web of Science ®Google Scholar
• Lazzari P, Fadda P, Marchese G, et al. Antinociceptive activity of Delta(9)-tetrahydrocannabinol non-ionic microemulsions. Int J Pharm. 2010;393:239–243.
   Google Scholar
• Simard P, Hoarau D, Khalid MN, et al. Preparation and in vivo evaluation of PEGylated spherulite formulations. Biochim Biophys Acta. 2005;1715:37–48.
   PubMed Web of Science ®Google Scholar
• Lu H, Li JB, Li M, et al. Systemic delivery of alpha-asarone with Kolliphor HS 15 improves its safety and therapeutic effect on asthma. Drug Deliv. 2015;22:266–275.
   PubMed Web of Science ®Google Scholar
• Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta. 2003;1609:102.
   PubMed Web of Science ®Google Scholar
• Litzinger DC, Buiting AMJ, van Rooijen N, et al. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Bba Biomembr. 1994;1190:99–107.
   PubMed Web of Science ®Google Scholar
• Song X, Jiang Y, Ren C, et al. Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study. Int J Nanomed. 2012;7:3689–3699.
   PubMed Web of Science ®Google Scholar
• Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta. 2004;1663:167–177.
   PubMed Web of Science ®Google Scholar
• Johnston MJW, Semple SC, Klimuk SK, et al. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Bba-Biomembr. 2006;1758:55–64.
   PubMed Web of Science ®Google Scholar
• Senior J, Delgado C, Fisher D, et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma-protein and clearance from the circulation - studies with poly(ethylene glycol)-coated vesicles. Biochimica Et Biophysica Acta. 1991;1062:77–82.
   PubMed Web of Science ®Google Scholar
• Blume G, Cevc G. Liposomes for the sustained drug release in vivo. Biochim Biophys Acta. 1990;1029:91–97.
   PubMed Web of Science ®Google Scholar
• Li W, Yi X, Liu X, et al. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. J Control Release. 2016;225:170–182.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliver Rev. 2013;65:36–48.
   PubMed Web of Science ®Google Scholar
• Song X, Wan Z, Chen T, et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment. Biomaterials 2016;108:44–56.
   PubMed Web of Science ®Google Scholar